Literature DB >> 23730407

Tumor-infiltrating PD1-Positive Lymphocytes and FoxP3-Positive Regulatory T Cells Predict Distant Metastatic Relapse and Survival of Clear Cell Renal Cell Carcinoma.

Myoung Jae Kang1, Kyoung Min Kim, Jun Sang Bae, Ho Sung Park, Ho Lee, Myoung Ja Chung, Woo Sung Moon, Dong Geun Lee, Kyu Yun Jang.   

Abstract

BACKGROUND: Clear cell renal cell carcinoma (CRCC) is the most common malignant tumor of the kidney, and the clinical outcome of CRCC is related with the metastatic potential of CRCC. A significant proportion of metastatic CRCC remains incurable. Recently, immunotherapy against specific targets such as programmed death 1 (PD1) has been adapted for fatal cases of CRCC.
MATERIALS AND METHODS: In this study, we aimed to evaluate the potential of tumor-infiltrating PD1-positive lymphocytes or FoxP3-positive regulatory T cells (Tregs) as predictors of the metastatic potential or prognosis of CRCC and investigate possible correlations with Epstein-Barr virus (EBV) infection in 199 cases of CRCC.
RESULTS: PD1 positivity, high Treg number, and EBV infection all predicted poor overall survival (OS) by univariate analysis. PD1 positivity and high Treg numbers were also significantly correlated with more distant metastatic relapse (DMR) and poor relapse-free survival (RFS) by univariate analysis. PD1 positivity and high Treg number were independent prognostic indicators for OS. In addition, PD1 positivity was an independent predictor of RFS and DMR. EBV infection was an independent predictor of OS of CRCC.
CONCLUSION: This study demonstrates that intratumoral infiltration of PD1-positive or FoxP3-positive lymphocytes can be used as significant prognostic indicators of CRCC and PD1 positivity could be very helpful in the prediction of latent distant metastasis of CRCCs. Therefore, evaluation of the infiltration of PD-positive cells or Tregs in CRCC may be useful diagnostic tools for the selection of patients who could benefit from PD1- or Treg-based immunotherapy.

Entities:  

Year:  2013        PMID: 23730407      PMCID: PMC3660796          DOI: 10.1593/tlo.13256

Source DB:  PubMed          Journal:  Transl Oncol        ISSN: 1936-5233            Impact factor:   4.243


  35 in total

1.  Localization of Epstein-Barr virus-encoded RNAs EBER-1 and EBER-2 in interphase and mitotic Burkitt lymphoma cells.

Authors:  M Schwemmle; M J Clemens; K Hilse; K Pfeifer; H Tröster; W E Müller; M Bachmann
Journal:  Proc Natl Acad Sci U S A       Date:  1992-11-01       Impact factor: 11.205

Review 2.  Targeting regulatory T cells in cancer.

Authors:  William L Byrne; Kingston H G Mills; James A Lederer; Gerald C O'Sullivan
Journal:  Cancer Res       Date:  2011-11-08       Impact factor: 12.701

3.  Immunoregulatory T cells in the peripheral blood of patients with Hodgkin's lymphoma.

Authors:  Sándor Baráth; Magdolna Aleksza; Katalin Keresztes; Judit Tóth; Sándor Sipka; Gyula Szegedi; Arpád Illés
Journal:  Acta Haematol       Date:  2006       Impact factor: 2.195

4.  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.

Authors:  Suzanne L Topalian; F Stephen Hodi; Julie R Brahmer; Scott N Gettinger; David C Smith; David F McDermott; John D Powderly; Richard D Carvajal; Jeffrey A Sosman; Michael B Atkins; Philip D Leming; David R Spigel; Scott J Antonia; Leora Horn; Charles G Drake; Drew M Pardoll; Lieping Chen; William H Sharfman; Robert A Anders; Janis M Taube; Tracee L McMiller; Haiying Xu; Alan J Korman; Maria Jure-Kunkel; Shruti Agrawal; Daniel McDonald; Georgia D Kollia; Ashok Gupta; Jon M Wigginton; Mario Sznol
Journal:  N Engl J Med       Date:  2012-06-02       Impact factor: 91.245

Review 5.  Regulatory T cells in cancer.

Authors:  Marc Beyer; Joachim L Schultze
Journal:  Blood       Date:  2006-08-01       Impact factor: 22.113

6.  Epstein-Barr virus infection in sarcomatoid renal cell carcinoma tissues.

Authors:  Kwang Hee Kim; Eun Mee Han; Eung Seok Lee; Hong Seok Park; Insun Kim; Young-Sik Kim
Journal:  BJU Int       Date:  2005-09       Impact factor: 5.588

7.  Epstein-Barr virus detection in kidney biopsy specimens correlates with glomerular mesangial injury.

Authors:  H Iwama; S Horikoshi; I Shirato; Y Tomino
Journal:  Am J Kidney Dis       Date:  1998-11       Impact factor: 8.860

8.  Increased prevalence of regulatory T-cells in the peripheral blood of patients with gastrointestinal cancer.

Authors:  Kazuhisa Tokuno; Shoichi Hazama; Shigefumi Yoshino; Shin Yoshida; Masaaki Oka
Journal:  Anticancer Res       Date:  2009-05       Impact factor: 2.480

9.  Expression of the Epstein-Barr virus-encoded Epstein-Barr virus nuclear antigen 1 in Hodgkin's lymphoma cells mediates Up-regulation of CCL20 and the migration of regulatory T cells.

Authors:  Karl R N Baumforth; Anna Birgersdotter; Gary M Reynolds; Wenbin Wei; Georgia Kapatai; Joanne R Flavell; Emma Kalk; Karen Piper; Steve Lee; Lee Machado; Kerry Hadley; Anne Sundblad; Jan Sjoberg; Magnus Bjorkholm; Anna A Porwit; Lee-Fah Yap; Soohwang Teo; Richard G Grundy; Lawrence S Young; Ingemar Ernberg; Ciaran B J Woodman; Paul G Murray
Journal:  Am J Pathol       Date:  2008-05-23       Impact factor: 4.307

10.  Prognostic significance of morphologic parameters in renal cell carcinoma.

Authors:  S A Fuhrman; L C Lasky; C Limas
Journal:  Am J Surg Pathol       Date:  1982-10       Impact factor: 6.394

View more
  49 in total

Review 1.  Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non-Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain Tumors.

Authors:  Shona Hendry; Roberto Salgado; Thomas Gevaert; Prudence A Russell; Tom John; Bibhusal Thapa; Michael Christie; Koen van de Vijver; M V Estrada; Paula I Gonzalez-Ericsson; Melinda Sanders; Benjamin Solomon; Cinzia Solinas; Gert G G M Van den Eynden; Yves Allory; Matthias Preusser; Johannes Hainfellner; Giancarlo Pruneri; Andrea Vingiani; Sandra Demaria; Fraser Symmans; Paolo Nuciforo; Laura Comerma; E A Thompson; Sunil Lakhani; Seong-Rim Kim; Stuart Schnitt; Cecile Colpaert; Christos Sotiriou; Stefan J Scherer; Michail Ignatiadis; Sunil Badve; Robert H Pierce; Giuseppe Viale; Nicolas Sirtaine; Frederique Penault-Llorca; Tomohagu Sugie; Susan Fineberg; Soonmyung Paik; Ashok Srinivasan; Andrea Richardson; Yihong Wang; Ewa Chmielik; Jane Brock; Douglas B Johnson; Justin Balko; Stephan Wienert; Veerle Bossuyt; Stefan Michiels; Nils Ternes; Nicole Burchardi; Stephen J Luen; Peter Savas; Frederick Klauschen; Peter H Watson; Brad H Nelson; Carmen Criscitiello; Sandra O'Toole; Denis Larsimont; Roland de Wind; Giuseppe Curigliano; Fabrice André; Magali Lacroix-Triki; Mark van de Vijver; Federico Rojo; Giuseppe Floris; Shahinaz Bedri; Joseph Sparano; David Rimm; Torsten Nielsen; Zuzana Kos; Stephen Hewitt; Baljit Singh; Gelareh Farshid; Sibylle Loibl; Kimberly H Allison; Nadine Tung; Sylvia Adams; Karen Willard-Gallo; Hugo M Horlings; Leena Gandhi; Andre Moreira; Fred Hirsch; Maria V Dieci; Maria Urbanowicz; Iva Brcic; Konstanty Korski; Fabien Gaire; Hartmut Koeppen; Amy Lo; Jennifer Giltnane; Marlon C Rebelatto; Keith E Steele; Jiping Zha; Kenneth Emancipator; Jonathan W Juco; Carsten Denkert; Jorge Reis-Filho; Sherene Loi; Stephen B Fox
Journal:  Adv Anat Pathol       Date:  2017-11       Impact factor: 3.875

2.  Do programmed death 1 (PD-1) and its ligand (PD-L1) play a role in patients with non-clear cell renal cell carcinoma?

Authors:  Mahmoud Abbas; Sandra Steffens; Maria Bellut; Jan U Becker; Anika Großhennig; Hendrik Eggers; Gerd Wegener; Markus A Kuczyk; Hans H Kreipe; Viktor Grünwald; Andres J Schrader; Philipp Ivanyi
Journal:  Med Oncol       Date:  2016-05-10       Impact factor: 3.064

Review 3.  New clinical advances in immunotherapy for the treatment of solid tumours.

Authors:  Valentina A Zavala; Alexis M Kalergis
Journal:  Immunology       Date:  2015-03-30       Impact factor: 7.397

Review 4.  Immunotherapy Is Changing First-Line Treatment of Metastatic Renal-Cell Carcinoma.

Authors:  Matthew K Labriola; Kristen A Batich; Jason Zhu; Megan A McNamara; Michael R Harrison; Andrew J Armstrong; Daniel J George; Tian Zhang
Journal:  Clin Genitourin Cancer       Date:  2019-02-05       Impact factor: 2.872

5.  Programmed cell death ligand 1 and tumor-infiltrating lymphocyte status in patients with renal cell carcinoma and sarcomatoid dedifferentiation.

Authors:  Fumi Kawakami; Kanishka Sircar; Jaime Rodriguez-Canales; Bryan M Fellman; Diana L Urbauer; Pheroze Tamboli; Nizar M Tannir; Eric Jonasch; Ignacio I Wistuba; Christopher G Wood; Jose A Karam
Journal:  Cancer       Date:  2017-08-22       Impact factor: 6.860

Review 6.  Coinhibitory molecule PD-1 as a potential target for the immunotherapy of multiple myeloma.

Authors:  D Atanackovic; T Luetkens; N Kröger
Journal:  Leukemia       Date:  2013-10-23       Impact factor: 11.528

Review 7.  Harnessing the PD-1 pathway in renal cell carcinoma: current evidence and future directions.

Authors:  Abhishek Tripathi; Charles G Drake; Lauren C Harshman
Journal:  BioDrugs       Date:  2014-12       Impact factor: 5.807

8.  FUT4 is involved in PD-1-related immunosuppression and leads to worse survival in patients with operable lung adenocarcinoma.

Authors:  Chang Liu; Zhi Li; Shuo Wang; Yibo Fan; Simeng Zhang; Xianghong Yang; Kezuo Hou; Jianhua Tong; Xuejun Hu; Xiaonan Shi; Xiaoxun Wang; Yunpeng Liu; Xiaofang Che; Xiujuan Qu
Journal:  J Cancer Res Clin Oncol       Date:  2018-10-24       Impact factor: 4.553

9.  The distribution of cutaneous metastases correlates with local immunologic milieu.

Authors:  Joshua M Schulman; Mariela L Pauli; Isaac M Neuhaus; Roberto Sanchez Rodriguez; Keyon Taravati; Uk Sok Shin; Timothy H McCalmont; Michael D Rosenblum
Journal:  J Am Acad Dermatol       Date:  2016-01-09       Impact factor: 11.527

10.  IL10 Release upon PD-1 Blockade Sustains Immunosuppression in Ovarian Cancer.

Authors:  Purushottam Lamichhane; Lavakumar Karyampudi; Barath Shreeder; James Krempski; Deborah Bahr; Joshua Daum; Kimberly R Kalli; Ellen L Goode; Matthew S Block; Martin J Cannon; Keith L Knutson
Journal:  Cancer Res       Date:  2017-10-09       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.